Clinical Trials Logo
  1. Home
  2. Active Rheumatoid Arthritis
  3. NCT06456489
  4. Details
NCT06456489 Clinical Trial

Pulse Steroid Injection in Refractory Rheumatoid Arthritis

Active Rheumatoid Arthritis Clinical Trial

Official title:
Revealing the Potential of Intravenous Pulse Steroid Therapy; Impressive Results in Attaining Remission or Low Disease Activity in Refractory Rheumatoid Arthritis

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06456489
Other study ID # Al-Azhar University
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 1, 2024
Est. completion date December 31, 2024

Study information
Verified date June 2024
Source Sohag University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Remission or low disease activity in active rheumatoid arthritis

Description:

Assessment of rheumatoid arthritis activity by Disease activity score DAS28, DAS28 Erythrocyte sedimentation rate (ESR), American college of rheumatology (ACR) 20, ACR 50, ACR 70 will be done at baseline and every month for 3 consecutive months for both groups.

Recruitment information / eligibility
Status Recruiting
Enrollment 268
Est. completion date December 31, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - Refractory rheumatoid arthritis patients Exclusion Criteria: - Other connective tissue diseases - Endocrine diseases such as DM and thyroid disorders

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Solumedrol
125 mg methylprednisolone intravenous pulse on 2 consecutive days

Locations
Country Name City State
Egypt Al-Azhar Univrsity Cairo

Sponsors (1)
Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary remission or low disease activity Outcome measurements for both groups will be done at baseline and every month for 3 months. DAS28, DAS28 ESR ACR20 ACR50 ACR70 4 months
See also
  Status Clinical Trial Phase
Completed NCT04472481 - Vitamin D Effect in Rheumatoid Arthritis. Phase 4
Completed NCT00913458 - Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis Phase 4
Completed NCT00959036 - Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis Phase 1/Phase 2
Completed NCT01961505 - Topical Compound Tripterygium Wilfordii Hook F for Patients With Active Rheumatoid Arthritis N/A
Completed NCT00393471 - Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis. Phase 3
Not yet recruiting NCT03346590 - Evolution of Total Energy Expenditure and Its Various Components in Active Rheumatoid Arthritis (RA)Treated With Anti-TNF Agents and Comparison With Healthy Subjects N/A
Terminated NCT02534896 - To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis Phase 3
Completed NCT03172325 - Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA Phase 3
Completed NCT00420199 - A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Phase 3
Completed NCT00882024 - Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA) Phase 2
Completed NCT03599986 - Clinical Efficacy and Safety of Leflunomide in Egyptian Patients With Active Rheumatoid Arthritis
Completed NCT02586246 - Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870 Phase 3
Completed NCT01008852 - Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis Phase 2